A Model To Produce CAR-T, Anywhere

Standardizing gene-modified cell therapy workflows allows clinical centers in underserved regions to bridge severe access gaps caused by high costs, long travel distances, and complex supply chain logistics. Implementing low-touch, vendor-agnostic cell processing paired with off-the-shelf, fully characterized CGMP lentiviral vectors accelerates the transition from concept to dosing.

By utilizing standardized vectors targeting clinically validated markers alongside flexible G-Rex expansion protocols, facilities can consistently achieve high transgene expression and viable cell yields from diverse donor starting materials. Coupled with comprehensive tech transfer programs, integrated quality attribute testing, and phase-appropriate regulatory support, this point-of-care model significantly shortens vein-to-vein timelines. Decoupling production from distant urban hubs enables local medical centers to lower per-dose costs and broaden scalable, life-saving therapies.

Access the full application note to explore detailed performance metrics and implementation strategies.